Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pertzye Clear all
Terminated Phase 1 Interventional Results available

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

NCT01142128
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

NCT02985801
View directory record Official record
Conditions
Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality
Interventions
Pancrelipase, Placebo Oral Capsule
Drug
Lead sponsor
Massimo Raimondo, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

NCT00408317
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Ultrase® MT20, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 3, 2026, 8:43 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions
NHS7108, Zenpep®
Drug
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fat Malabsorption in Chronic Pancreatitis

NCT02849704
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Creon36™
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
30 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

NCT00513682
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT20
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

NCT00559052
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
VIOKASE 16
Drug
Lead sponsor
Axcan Pharma
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida • Mayo Clinic- Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Early Phase 1 Interventional Results available

Pancreatic Enzyme Replacement and Glucose Regulation in Type 1 Diabetes

NCT05266963
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CREON, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 3, 2026, 8:43 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

NCT04098237
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Pancrelipase
Drug
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Results available

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

NCT01663272
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CABOZANTINIB, gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 3, 2026, 8:43 AM EDT
Recruiting Phase 4 Interventional

Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency

NCT06477159
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
Pancrelipase Capsules
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT03859869
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Interventions
Pancrelipase, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy

NCT00414908
View directory record Official record
Conditions
Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase delayed release capsule, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Scottsdale, Arizona • Bristol, Connecticut • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

NCT00981214
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 7 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT00775528
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions
Pancrelipase Delayed Release
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
1 Month to 6 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

NCT02372383
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ethambutol, Rifampin, Azithromycin, Pancrelipase
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 4 Interventional

Irritable Bowel Syndrome Evaluation and Treatment in Primary Care

NCT01641341
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Bifidobacterium infantis, Pancrelipase, Nitazoxanide, Placebo
Drug
Lead sponsor
American Academy of Family Physicians
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Lomita, California • Leawood, Kansas • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 3, 2026, 8:43 AM EDT
Not listed Not applicable Interventional

Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

NCT01771146
View directory record Official record
Conditions
Pancreas Cancer, Localized Pancreas Cancer, Non-metastatic Pancreas Cancer
Interventions
FOLFIRINOX Regimen
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

NCT00432861
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
PANCRECARB® (pancrelipase), Placebo
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

NCT00880100
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT12
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Years to 6 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
15
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 3, 2026, 8:43 AM EDT
Terminated Phase 4 Interventional Results available

Pancreatic Enzyme Supplementation for Celiac Disease

NCT02475369
View directory record Official record
Conditions
Celiac Disease
Interventions
pancrelipase
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 3, 2026, 8:43 AM EDT
Completed No phase listed Observational

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

NCT04949828
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
CREON
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 3, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT03924947
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Ventura, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 3, 2026, 8:43 AM EDT